Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TC-5214 as Adjunct in MDD (RENAISSANCE 2)
NCT01157078Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2010
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing TC-5214 + SSRI/SNRI with Placebo + SSRI/SNRI (2 arms). Primary endpoint: Montgomery-Asberg Depression Rating Scale Total Score at 16 weeks. Started Jun 2010; status: completed.
02
Drugs
dexmecamylamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01157078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01157078.